Singh Naresh, Sharma Samantha
Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN 46202, United States.
World J Gastroenterol. 2024 Jul 14;30(26):3257-3260. doi: 10.3748/wjg.v30.i26.3257.
Over the years immunotherapy has demonstrably improved the field of cancer treatment. However, achieving long-term survival for colorectal cancer (CRC) patients remains a significant unmet need. Combination immunotherapies incorporating targeted drugs like MEK or multi-kinase inhibitors have offered some palliative benefit. Nevertheless, substantial gaps remain in the current therapeutic armamentarium for CRC. In recent years, there has been a surge of interest in exploring novel treatment strategies, including the application of light-activated drugs in conjunction with optical devices. This approach holds promise for achieving localized and targeted delivery of cytotoxic agents, such as microtubule-targeting drugs, directly to cancerous cells within the colon.
多年来，免疫疗法已显著改善了癌症治疗领域。然而，实现结直肠癌（CRC）患者的长期生存仍然是一个重大的未满足需求。包含MEK等靶向药物或多激酶抑制剂的联合免疫疗法已带来了一些姑息性益处。尽管如此，目前CRC的治疗手段仍存在很大差距。近年来，人们对探索新型治疗策略的兴趣激增，包括将光激活药物与光学设备结合应用。这种方法有望将细胞毒性药物（如微管靶向药物）直接局部靶向递送至结肠内的癌细胞。
